login

Quality of life assessment in clinical cancer research

British Journal of CancerPublished 1 July 1994Open access
Manfred Olschewski, Gabi Schulgen, Martin Schumacher, DG Altman
Citations90
SJR quartileQ1
SJR score3.14
SNIP1.83
View PDF

TL;DR

In attempting to reach a more comprehensive evaluation of treatment efficacy beyond the objective aspects of achieving optimal survival, maximal tumour response and minimal toxicity, additional end-points in cancer clinical trials were introduced that take into account the subjective response of the patients to their illness and its treatment.

Abstract

Classical end-points in clinical therapeutic trials in oncology are usually defined by total, recurrence-free or systemic disease-free survival.Primarily, these allow an adequate de- scription of the biological course of the disease.In current

Keywords

MedicineEconomics, Econometrics and Finance